Imiquimod

Summary

Imiquimod (CHEMBL1282) is an approved small-molecule antineoplastic agent (ATC D06BB10) targeting TLR7; indicated across 54 conditions including actinic keratosis and basal cell carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06BB10
• Targets: 1 (TLR7)
• Indications: 54 conditions
• Clinical trials: 145
• Chemistry: 240.3 Da · C14H16N4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1282
Name	Imiquimod
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	57469
ChEBI	CHEBI:36704
ATC	D06BB10
Molecular formula	C14H16N4
Molecular weight	240.3
InChIKey	DOUYETYNHWVLEO-UHFFFAOYSA-N

SMILES: CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N

IUPAC name: 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine

ChEBI definition: An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.

Pharmacological roles (ChEBI): antineoplastic agent, interferon inducer.

Also known as: Aldara, Imiquimod, NSC-369100, NSC-759651, R-837, S-26308, S26308, Tmx-101, Zartra, Zyclara, imiquimod, SID865810

Patent coverage: 14,352 distinct patent families (56,604 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 55,317 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TLR7	TLR7	Agonist	4.94	0.2%	Q9NYK1

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Prelamin-A/C, 5-hydroxytryptamine receptor 2B, Histamine H2 receptor, Alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 2A, Alpha-1A adrenergic receptor, DNA polymerase beta, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A2a, 3’,5’-cyclic-AMP phosphodiesterase 4D, Oxidized purine nucleoside triphosphate hydrolase, Toll-like receptor 7.

Bioactivity

ChEMBL activities: 17 potent at pChembl ≥ 5 of 26 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TLR7	6.7	EC50	202	nM	CHEMBL_ACT_25884828
NUDT1	6.19	IC50	646	nM	CHEMBL_ACT_22422569
ADRA1D	5.89	Ki	1288	nM	CHEMBL_ACT_7654102
HRH2	5.83	Ki	1481	nM	CHEMBL_ACT_7656216
HRH2	5.82	IC50	1506	nM	CHEMBL_ACT_7656215
TLR7	5.67	EC50	2120	nM	CHEMBL_ACT_25535206
TLR7	5.67	EC50	2120	nM	CHEMBL_ACT_3312624
TLR7	5.66	EC50	2210	nM	CHEMBL_ACT_24985522
ADRA1D	5.58	IC50	2621	nM	CHEMBL_ACT_7654101
ADORA2A	5.53	Ki	2987	nM	CHEMBL_ACT_7654092
PDE4D	5.39	AC50	4025	nM	CHEMBL_ACT_25184917
ADORA2A	5.27	IC50	5320	nM	CHEMBL_ACT_7654091
ADRA1A	5.25	AC50	5671	nM	CHEMBL_ACT_25137693
HTR2A	5.25	AC50	5584	nM	CHEMBL_ACT_25173475
TLR7	5.21	EC50	6200	nM	CHEMBL_ACT_19047388
TLR7	5.17	EC50	6800	nM	CHEMBL_ACT_20601058
TLR7	5.08	EC50	8290	nM	CHEMBL_ACT_25864953

Target pathways

Aggregated over 1 target gene(s): TLR7.

Top Reactome pathways

11 total, by targets touching each:

Pathway	Targets	Genes
Trafficking and processing of endosomal TLR	1	TLR7
Toll Like Receptor 7/8 (TLR7/8) Cascade	1	TLR7
Regulation of TLR by endogenous ligand	1	TLR7
Potential therapeutics for SARS	1	TLR7
SARS-CoV-1 activates/modulates innate immune responses	1	TLR7
SARS-CoV-2 activates/modulates innate and adaptive immune responses	1	TLR7
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling	1	TLR7
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	1	TLR7
MyD88 dependent cascade initiated on endosome	1	TLR7
Defective regulation of TLR7 by endogenous ligand	1	TLR7
RSV-host interactions	1	TLR7

Dominant GO biological processes

GO term	Targets
toll-like receptor signaling pathway	1
inflammatory response	1
canonical NF-kappaB signal transduction	1
JNK cascade	1
positive regulation of chemokine production	1
positive regulation of interferon-alpha production	1
positive regulation of interferon-beta production	1
positive regulation of type II interferon production	1
positive regulation of interleukin-6 production	1
positive regulation of interleukin-8 production	1
toll-like receptor 7 signaling pathway	1
toll-like receptor 8 signaling pathway	1
positive regulation of canonical NF-kappaB signal transduction	1
innate immune response	1
positive regulation of transcription by RNA polymerase II	1

Indications & clinical

Indications

5 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
actinic keratosis	4	MONDO:0005173	EFO:0002496
basal cell carcinoma	4	MONDO:0020804	EFO:0004193
viral infectious disease	4	MONDO:0005108	EFO:0000763
anogenital human papillomavirus infection	4	MONDO:0005647	EFO:0007147
keratosis	4	MONDO:0006566	EFO:1000720

39 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
vulvar intraepithelial neoplasia	3	MONDO:0005198	EFO:0002627
human papilloma virus infection	3	MONDO:0005161	EFO:0001668
cutaneous leishmaniasis	3	MONDO:0005446	EFO:0005046
extramammary Paget disease	3	MONDO:0008177	EFO:1000249
localized scleroderma	3	MONDO:0019562	EFO:1001361
influenza	3	MONDO:0005812	EFO:0007328
dysplasia of cervix	3	MONDO:0006736	MONDO:0022394
melanoma	2	MONDO:0005105	EFO:0000756
cervical carcinoma	2	MONDO:0005131	EFO:0001061
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
leukemia	2	MONDO:0005059	EFO:0000565
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
hepatitis B virus infection	2	MONDO:0005344	EFO:0004197
hemangioma	2	MONDO:0006500	EFO:1000635
keloid	2	MONDO:0005348	EFO:0004212
kidney failure	2	MONDO:0001106	EFO:1002048
breast neoplasm	2	MONDO:0021100	MONDO:0007254
in situ carcinoma	2	MONDO:0004647	MONDO:0024474
cirrhosis of liver	2	MONDO:0005155	EFO:0001422
Bowen disease of the skin	2	MONDO:0020761	MONDO:0020761
glioblastoma	1	MONDO:0018177	EFO:0000519
prostate adenocarcinoma	1	MONDO:0005082	EFO:0000673
squamous cell carcinoma	1	MONDO:0005096	EFO:0000707
anaplastic astrocytoma	1	MONDO:0016684	EFO:0002499
medulloblastoma	1	MONDO:0007959	EFO:0002939
ependymoma	1	MONDO:0016698	EFO:1000028
colorectal carcinoma	1	MONDO:0024331	EFO:1001951
soft tissue sarcoma	1	MONDO:0018078	EFO:1001968
acute lymphoblastic leukemia	1	MONDO:0004967	EFO:0000220
avian influenza	1	MONDO:0018695	EFO:0005222
diffuse intrinsic pontine glioma	1	MONDO:0006033	EFO:1000026
brain cancer	1	MONDO:0001657	MONDO:0001657
cheilitis	1	MONDO:0002102	MONDO:0002102
glioma	1	MONDO:0021042	MONDO:0100342
osteosarcoma	1	MONDO:0009807	MONDO:0021054
neoplasm	1	MONDO:0005070	MONDO:0004992
brain neoplasm	1	MONDO:0021211	EFO:0003833
paraganglioma	1	MONDO:0000448	EFO:1000453

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 145.

Phase distribution

Phase	Trials
PHASE3	30
PHASE1	30
PHASE2	27
PHASE4	20
Not specified	19
PHASE1/PHASE2	7
EARLY_PHASE1	7
PHASE2/PHASE3	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06356012	PHASE4	RECRUITING	Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod
NCT06840470	PHASE4	ACTIVE_NOT_RECRUITING	Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia
NCT00116649	PHASE4	COMPLETED	Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
NCT00189293	PHASE4	COMPLETED	Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
NCT00204555	PHASE4	COMPLETED	Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma
NCT00314756	PHASE4	COMPLETED	Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
NCT00581425	PHASE4	COMPLETED	Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
NCT00761371	PHASE4	COMPLETED	Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients
NCT00774787	PHASE4	COMPLETED	Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
NCT00777127	PHASE4	COMPLETED	Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses
NCT00803907	PHASE4	UNKNOWN	Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
NCT00849992	PHASE4	COMPLETED	Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy
NCT01059110	PHASE4	TERMINATED	Comparison of Five Treatments in Patients With Plantar Warts
NCT01161888	PHASE4	COMPLETED	Effect of Topical Imiquimod on Lentigo Maligna
NCT01203878	PHASE4	TERMINATED	Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
NCT01453179	PHASE4	COMPLETED	Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
NCT01538901	PHASE4	TERMINATED	Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients
NCT01663558	PHASE4	WITHDRAWN	Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV
NCT02281682	PHASE4	UNKNOWN	IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
NCT04842422	PHASE4	COMPLETED	Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
NCT00066872	PHASE3	COMPLETED	Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
NCT00129519	PHASE3	COMPLETED	A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
NCT00147771	PHASE3	COMPLETED	Imiquimod in Children With Plaque Morphea
NCT00175643	PHASE3	COMPLETED	Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses
NCT00189241	PHASE3	COMPLETED	A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
NCT00189280	PHASE3	COMPLETED	Aldara for the Treatment of Large and/or Multiple sBCC
NCT00189306	PHASE3	COMPLETED	Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
NCT00230373	PHASE3	WITHDRAWN	Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study
NCT00257530	PHASE3	COMPLETED	Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
NCT00294320	PHASE3	COMPLETED	Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
NCT00384124	PHASE2/PHASE3	UNKNOWN	Topical Imiquimod for Bowen’s Disease of the Head and Neck
NCT00603798	PHASE3	COMPLETED	Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
NCT00605176	PHASE3	COMPLETED	Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
NCT00674739	PHASE3	COMPLETED	Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
NCT00859105	PHASE3	COMPLETED	A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis
NCT00894647	PHASE3	COMPLETED	Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
NCT00941252	PHASE2/PHASE3	COMPLETED	ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial
NCT00948428	PHASE3	COMPLETED	Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
NCT01088737	PHASE2/PHASE3	UNKNOWN	Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
NCT01283763	PHASE3	TERMINATED	Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia
NCT01861535	PHASE3	COMPLETED	Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia
NCT02059499	PHASE3	COMPLETED	Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
NCT02103023	PHASE3	COMPLETED	Intradermal Influenza Vaccine in the Young
NCT02120898	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
NCT02130323	PHASE2/PHASE3	COMPLETED	Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix
NCT02135419	PHASE3	COMPLETED	Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
NCT02242929	PHASE3	UNKNOWN	Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma
NCT02329171	PHASE3	TERMINATED	Imiquimod Treatment of CIN Lesions
NCT02385188	PHASE3	COMPLETED	Topical 5% Imiquimod Cream for Vulvar Paget’s Disease
NCT02394132	PHASE3	COMPLETED	Radiotherapy or Imiquimod in Complex Lentigo Maligna
NCT02669459	PHASE3	UNKNOWN	Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol
NCT03289260	PHASE3	UNKNOWN	Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial
NCT03307902	PHASE2/PHASE3	COMPLETED	ID HBV Vaccination With Imiquimod in OBI
NCT03901690	PHASE3	UNKNOWN	Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study
NCT04143451	PHASE3	UNKNOWN	Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients
NCT00799110	PHASE2	ACTIVE_NOT_RECRUITING	Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
NCT07251413	PHASE1/PHASE2	RECRUITING	Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
NCT00031759	PHASE2	COMPLETED	Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia
NCT00189267	PHASE2	COMPLETED	A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
NCT00273910	PHASE2	COMPLETED	Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
NCT00596336	PHASE2	TERMINATED	Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients
NCT00601016	PHASE2	COMPLETED	A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy
NCT00651703	PHASE2	COMPLETED	Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
NCT00785122	PHASE1/PHASE2	COMPLETED	IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
NCT00821964	PHASE2	COMPLETED	Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
NCT00899574	PHASE2	COMPLETED	Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
NCT00941811	PHASE2	COMPLETED	Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment
NCT00979550	PHASE2	TERMINATED	The Effects of Aldara as an Adjunct to Laser Treatment
NCT01380314	PHASE2	COMPLETED	Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
NCT01421017	PHASE1/PHASE2	COMPLETED	Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
NCT01593124	PHASE2	COMPLETED	Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation
NCT01731652	PHASE2	COMPLETED	Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
NCT01909752	PHASE2	COMPLETED	Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
NCT02078648	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
NCT02224599	PHASE1/PHASE2	TERMINATED	Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
NCT02452307	PHASE1/PHASE2	UNKNOWN	Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
NCT02482428	PHASE2	COMPLETED	Efficacy and Tolerability of Topical LFX453 for External Genital Warts
NCT02802943	PHASE2	COMPLETED	iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
NCT02864147	PHASE2	COMPLETED	Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
NCT02960815	PHASE2	COMPLETED	Imiquimod and Influenza Vaccine for Immunocompromised Patients
NCT03180684	PHASE2	COMPLETED	Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
NCT03233412	PHASE2	COMPLETED	Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions
NCT03534947	PHASE2	COMPLETED	A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
NCT03559413	PHASE1/PHASE2	COMPLETED	Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
NCT03760250	PHASE2	TERMINATED	Imiquimod for Preventing Keloid Recurrence
NCT03914417	PHASE2	COMPLETED	Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
NCT05028322	PHASE2	UNKNOWN	Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD’s Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen
NCT05314127	PHASE2	UNKNOWN	Efficacy of Tazarotene in Treatment of Verruca Plana
NCT05740969	PHASE2	UNKNOWN	Gene and Protein Expression Profiles After Treatment of Actinic Keratoses
NCT02600949	PHASE1	RECRUITING	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
NCT03872947	PHASE1	ACTIVE_NOT_RECRUITING	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
NCT04808245	PHASE1	ACTIVE_NOT_RECRUITING	A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
NCT00079300	PHASE1	COMPLETED	Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
NCT00118313	PHASE1	COMPLETED	Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
NCT00142454	PHASE1	COMPLETED	NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
NCT00453050	PHASE1	COMPLETED	Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
NCT00638651	PHASE1	COMPLETED	Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal
NCT00788164	PHASE1	COMPLETED	Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
NCT00828568	PHASE1	COMPLETED	Bioequivalence Study of Two Imiquimod Cream 5%
NCT00865644	PHASE1	COMPLETED	Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

7 molecules share ≥1 primary target. Top 7 by shared-target count:

Molecule	Source	Status	Shared targets
HYDROXYCHLOROQUINE	ChEMBL	Phase 4 (approved)	TLR7
AFIMETORAN	ChEMBL	Phase 2	TLR7
CPG-52852	ChEMBL	Phase 2	TLR7
GSK-2245035	ChEMBL	Phase 2	TLR7
MHV-370	ChEMBL	Phase 2	TLR7
RESIQUIMOD	ChEMBL	Phase 2	TLR7
VESATOLIMOD	ChEMBL	Phase 2	TLR7